Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CIMZIA vs CARDURA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Certolizumab pegol is a recombinant, humanized antibody Fab' fragment conjugated to polyethylene glycol (PEG) that binds and neutralizes human tumor necrosis factor alpha (TNFα), preventing its interaction with cell surface TNF receptors (TNFR p55 and p75). It also modulates immune responses by inhibiting TNFα-induced pro-inflammatory cytokine production and adhesion molecule expression.
Selective antagonist of alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and prostate.
Crohn's disease (FDA approved for adults with moderately to severely active disease),Rheumatoid arthritis (FDA approved for adults with moderately to severely active disease),Psoriatic arthritis (FDA approved for adults),Ankylosing spondylitis (FDA approved for adults),Plaque psoriasis (off-label use),Axial spondyloarthritis (off-label use)
Hypertension,Benign prostatic hyperplasia
400 mg subcutaneously at weeks 0, 2, and 4, then 200 mg every 2 weeks or 400 mg every 4 weeks.
Initial: 1 mg orally once daily, titrated based on standing blood pressure response up to 16 mg daily as a single dose or divided twice daily. Maximum: 16 mg/day.
14 days (range 11-17 days) following subcutaneous administration; supports every 2-week or monthly dosing intervals.
Terminal elimination half-life is approximately 22 hours, allowing once-daily dosing; peak effect on blood pressure occurs at 2-6 hours post-dose.
Certolizumab pegol is a monoclonal antibody fragment that is not metabolized by cytochrome P450 enzymes. It is degraded by proteolysis into small peptides and amino acids.
Extensively metabolized in the liver via O-demethylation and hydroxylation; CYP3A4 is the major enzyme involved.
Primarily eliminated via reticuloendothelial system and proteolytic catabolism; no significant renal or biliary excretion. Clinical pharmacokinetic studies show no dose adjustment needed in renal impairment.
Primarily hepatic metabolism (approx. 60-70%) with biliary excretion of metabolites; renal excretion accounts for about 30-40% of the dose, mainly as metabolites with <5% unchanged drug.
Not applicable (monoclonal antibody); typically does not bind to serum proteins other than target antigen.
98-99% bound to plasma proteins (primarily albumin).
~5.7 L (approx. 0.08 L/kg for a 70 kg patient), indicating predominant distribution in vascular space with limited extravascular penetration.
0.5-1.0 L/kg (approximately 50-70 L in adults); indicates extensive extravascular distribution.
Subcutaneous: ~80% (range 63-92%) relative to intravenous administration.
Oral bioavailability is approximately 65% (range 43-81%) with minimal first-pass effect.
No dose adjustment required for renal impairment. Not studied in severe renal impairment.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, start with 0.5 mg daily and titrate cautiously due to increased sensitivity.
No dose adjustment required for hepatic impairment. Not studied in severe hepatic impairment (Child-Pugh C).
Child-Pugh A: Start at 0.5 mg daily. Child-Pugh B or C: Contraindicated due to extensive hepatic metabolism.
Not approved for use in pediatric patients. Safety and efficacy not established.
Safety and efficacy not established in pediatric patients; use not recommended.
No specific dose adjustment in elderly; use with caution due to increased infection risk.
Initiate at 0.5 mg daily due to increased risk of orthostatic hypotension. Titrate slowly based on tolerability and response.
Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to opportunistic pathogens. Malignancies, including lymphoma, have been reported in children and adolescents treated with TNF blockers.
None
Serious infections (reactivation of TB, fungal infections, bacterial sepsis), malignancies (including lymphoma and non-melanoma skin cancer), hepatitis B virus reactivation, demyelinating disease (e.g., multiple sclerosis), congestive heart failure (new onset or exacerbation), hematologic abnormalities (pancytopenia, aplastic anemia), hypersensitivity reactions (including anaphylaxis), and lupus-like syndrome.
Orthostatic hypotension and syncope, especially with first dose,Use with caution in patients with hepatic impairment,Risk of priapism,Intraoperative floppy iris syndrome during cataract surgery
Active serious infection, including sepsis, tuberculosis, and opportunistic infections. Known hypersensitivity to certolizumab pegol or any of its components.
Hypersensitivity to doxazosin or other quinazolines
No known food interactions. Take with or without food. No dietary restrictions required.
Avoid grapefruit and grapefruit juice as they may increase doxazosin levels. Take with food to reduce gastrointestinal upset. No other significant food interactions.
CIMZIA (certolizumab pegol) is a PEGylated Fc-free anti-TNF monoclonal antibody. Due to minimal placental transfer (low Fc receptor binding), first trimester exposure shows no increased risk of major birth defects. Limited data in second and third trimesters; theoretical risk of immunosuppression in fetus. No known teratogenic effect in animal studies.
Pregnancy Category C. First trimester: No evidence of teratogenicity in animal studies; limited human data. Second/third trimesters: Potential risk of fetal hypotension and hypoxia from maternal hypotension. Avoid use in pregnancy unless benefit outweighs risk.
Minimal transfer into breast milk due to high molecular weight and PEGylation. M/P ratio not established. Consider benefits of breastfeeding vs risk of infant exposure. American Academy of Pediatrics considers compatible with breastfeeding.
Excreted in human milk; M/P ratio unknown. Caution due to potential for hypotension in nursing infants. Use only if essential.
No standard dose adjustment required. Pharmacokinetics not significantly altered in pregnancy due to low placental transfer. Continue standard dosing; delay live vaccines in infants for 6 months after last maternal dose.
No established dose adjustments for pregnancy; use lowest effective dose due to potential for increased clearance and changes in volume of distribution.
CIMZIA (certolizumab pegol) is a PEGylated Fc-free anti-TNF monoclonal antibody. It lacks an Fc region, which reduces placental transfer, making it a preferred biologic for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease during pregnancy. Administer subcutaneously. Monitor for infections, including TB reactivation. Do not administer live vaccines concurrently. Injection site reactions are common; pre-medication with antihistamines may reduce them.
CARDURA (doxazosin) is an alpha-1 blocker used for hypertension and benign prostatic hyperplasia (BPH). First-dose syncope is more common with immediate-release (IR) than extended-release (GITS). Start IR at 1 mg at bedtime and titrate slowly. GITS formulation minimizes orthostatic effects. Monitor blood pressure carefully in elderly patients. May cause intraoperative floppy iris syndrome (IFIS) during cataract surgery; do not stop therapy preoperatively. Avoid use in patients with orthostatic hypotension or micturition syncope.
Do not receive live vaccines (e.g., MMR, nasal flu, yellow fever) while on CIMZIA. Discuss vaccination schedule with your doctor.,Report any signs of infection (fever, cough, painful urination) or allergic reactions (rash, difficulty breathing) immediately.,Store CIMZIA in the refrigerator at 2°C to 8°C. Do not freeze. Protect from light. Allow to reach room temperature before injection.,Use proper injection technique; rotate injection sites (abdomen, thigh). Discard unused portions in a sharps container.,Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. CIMZIA has low placental transfer and may be used during pregnancy.
Take the first dose at bedtime to minimize dizziness. Sit or lie down if you feel lightheaded.,Avoid sudden position changes; rise slowly from sitting or lying positions.,May cause dizziness, drowsiness, or blurred vision. Do not drive until you know how CARDURA affects you.,For BPH, it may take up to 2 weeks to improve symptoms. Do not stop medication abruptly.,Inform your surgeon if you are scheduled for cataract surgery; CARDURA may affect eye surgery outcomes.,Avoid alcohol, which can worsen side effects like dizziness and low blood pressure.,For hypertension, continue regular monitoring with your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CIMZIA vs CARDURA, answered by our medical review team.
CIMZIA is a TNF-alpha Inhibitor that works by Certolizumab pegol is a recombinant, humanized antibody Fab' fragment conjugated to polyethylene glycol (PEG) that binds and neutralizes human tumor necrosis factor alpha (TNFα), preventing its interaction with cell surface TNF receptors (TNFR p55 and p75). It also modulates immune responses by inhibiting TNFα-induced pro-inflammatory cytokine production and adhesion molecule expression.. CARDURA is a Alpha-1 Blocker Antihypertensive that works by Selective antagonist of alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and prostate.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CIMZIA and CARDURA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CIMZIA is: 400 mg subcutaneously at weeks 0, 2, and 4, then 200 mg every 2 weeks or 400 mg every 4 weeks.. The standard adult dose of CARDURA is: Initial: 1 mg orally once daily, titrated based on standing blood pressure response up to 16 mg daily as a single dose or divided twice daily. Maximum: 16 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CIMZIA and CARDURA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CIMZIA is classified as Category C. CIMZIA (certolizumab pegol) is a PEGylated Fc-free anti-TNF monoclonal antibody. Due to minimal placental transfer (low Fc receptor binding), first trimester exposure shows no incr. CARDURA is classified as Category C. Pregnancy Category C. First trimester: No evidence of teratogenicity in animal studies; limited human data. Second/third trimesters: Potential risk of fetal hypotension and hypoxia. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.